JP2019536767A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536767A5 JP2019536767A5 JP2019523821A JP2019523821A JP2019536767A5 JP 2019536767 A5 JP2019536767 A5 JP 2019536767A5 JP 2019523821 A JP2019523821 A JP 2019523821A JP 2019523821 A JP2019523821 A JP 2019523821A JP 2019536767 A5 JP2019536767 A5 JP 2019536767A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- inhibitor
- epicatechin
- compounds
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002401 inhibitory effect Effects 0.000 claims 18
- 239000003112 inhibitor Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 10
- 230000001093 anti-cancer Effects 0.000 claims 8
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- -1 nitoseurea Chemical compound 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 3
- 235000007246 (+)-epicatechin Nutrition 0.000 claims 3
- 229930013783 (-)-epicatechin Natural products 0.000 claims 3
- 235000007355 (-)-epicatechin Nutrition 0.000 claims 3
- 229930003335 epicatechin Natural products 0.000 claims 3
- 235000012734 epicatechin Nutrition 0.000 claims 3
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 Carboplatin Drugs 0.000 claims 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 2
- 229960002949 Fluorouracil Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- 230000000259 anti-tumor Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 2
- HKTBGLYNZWOCKW-NSHDSACASA-N 4-[[4-(2-amino-1,3-thiazol-5-yl)-6-[(3S)-3-methylmorpholin-4-yl]-1,3,5-triazin-2-yl]oxy]-3-fluoro-N,N-dimethylbenzamide Chemical compound C[C@H]1COCCN1C1=NC(OC=2C(=CC(=CC=2)C(=O)N(C)C)F)=NC(C=2SC(N)=NC=2)=N1 HKTBGLYNZWOCKW-NSHDSACASA-N 0.000 claims 1
- BQPZIYSVGQSCET-UHFFFAOYSA-N 4-[[4-(2-amino-1,3-thiazol-5-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]-N,N-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1OC1=NC(N2CCOCC2)=NC(C=2SC(N)=NC=2)=N1 BQPZIYSVGQSCET-UHFFFAOYSA-N 0.000 claims 1
- POAZEDQQRWSVGZ-ZDUSSCGKSA-N 4-[[4-(6-aminopyridin-3-yl)-6-[(3S)-3-methylmorpholin-4-yl]-1,3,5-triazin-2-yl]oxy]-3-fluoro-N,N-dimethylbenzamide Chemical compound C[C@H]1COCCN1C1=NC(OC=2C(=CC(=CC=2)C(=O)N(C)C)F)=NC(C=2C=NC(N)=CC=2)=N1 POAZEDQQRWSVGZ-ZDUSSCGKSA-N 0.000 claims 1
- BQRTZZXEYYXREE-UHFFFAOYSA-N 4-[[4-(6-aminopyridin-3-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]-N,N-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1OC1=NC(N2CCOCC2)=NC(C=2C=NC(N)=CC=2)=N1 BQRTZZXEYYXREE-UHFFFAOYSA-N 0.000 claims 1
- 108060006693 ABL Proteins 0.000 claims 1
- 102100019002 ABL1 Human genes 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 102100011141 ALK Human genes 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 101700004551 BRAF Proteins 0.000 claims 1
- 102100004328 BRAF Human genes 0.000 claims 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 101710003421 FGF Proteins 0.000 claims 1
- 102100004573 FLT3 Human genes 0.000 claims 1
- 101710009074 FLT3 Proteins 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 101700034277 JAK1 Proteins 0.000 claims 1
- 102100019517 JAK1 Human genes 0.000 claims 1
- 102100019518 JAK3 Human genes 0.000 claims 1
- 101700007593 JAK3 Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 101700067074 MAPK Proteins 0.000 claims 1
- 101710041325 MAPKAPK2 Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 1
- 229960003048 Vinblastine Drugs 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 230000000973 chemotherapeutic Effects 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 230000002414 glycolytic Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitors Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001024 immunotherapeutic Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 230000002503 metabolic Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000003197 protein kinase b inhibitor Substances 0.000 claims 1
- 101710024887 rl Proteins 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 101700045897 spk-1 Proteins 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims 1
Claims (14)
- エピカテキンと少なくとも1つの抗癌化合物の組合せ。
- 前記エピカテキンが、(+)−エピカテキン、(−)−エピカテキン、及び(+)−エピカテキンと(−)−エピカテキンの混合物からなる群から選択される、請求項1に記載の組合せ。
- (+)−エピカテキン:(−)−エピカテキンの比率が0.1:99.9〜99.9:0.1の範囲内である、請求項1に記載の組合せ。
- エピカテキン:抗癌化合物の比率が、0.1:99.9〜99.9:0.1の範囲内である、請求項1に記載の組合せ。
- 前記抗癌化合物が、シクロホスファミド、ニトソウレア、アルコールスルホネート、アルキル化抗腫瘍化合物;シスプラチン、カルボプラチン、オキサリプラチン、白金配位化合物;メトトレキサート、6−メルカプトプリン、5−フルオロウラシル(5−FU)、ゲムシタビン、代謝拮抗薬;ドキソルビシン、抗腫瘍抗薬;ドセタキセル、パクリタキセル、トポテカン、エトポシド、イリノテカン、ビンブラスチン、微小管阻害薬;イマチニブ、ラパチニブ、スニチニブ、ソラフェニブ、テムシロリムス、生物学的化合物;イバンドロン酸、ゾレドロン酸、ビスホスホネート;免疫療法化合物;標的抗癌療法化合物;選択的又は非選択的なPI3キナーゼ阻害薬、mTOR阻害薬、MEK阻害薬、Akt阻害薬、EGF受容体を標的とするイマチニブ、エルロチニブ、ゲフィチニブ、チロシンキナーゼ阻害薬;FGF、VEGF、PDGFに対するスニチニブ阻害薬;ALK阻害薬、ABL阻害薬、SCR阻害薬、FLT3阻害薬、KIT阻害薬、MET阻害薬、BRAF阻害薬、Ilβ阻害薬、JAK1/2阻害薬、JAK3阻害薬、プロテオソーム阻害薬ボルテゾミブ、他の成長因子阻害薬、RAS/RAF/MAPK経路の阻害薬、他のシグナル伝達阻害薬、多標的キナーゼ阻害薬、トポイソメラーゼ阻害薬、解糖系阻害薬、カテプシンB阻害薬、及びヒストン脱アセチル化酵素阻害薬からなる群から選択される、請求項1に記載の組合せ。
- 前記抗癌化合物が、シスプラチン、カルボプラチン、オキサリプラチン、白金含有抗癌剤、PI3キナーゼ/mTOR阻害薬、及び化学療法化合物からなる群から選択される、請求項1に記載の組合せ。
- PI3キナーゼ/mTORを有する抗癌化合物が、以下の化合物からなる群から選択される、請求項1及び5に記載の組合せ:
i.4−(4−(2−アミノチアゾール−5−イル)−6−モルホリノ−1,3,5−トリアジン−2−イルオキシ)−N,N−ジメチルベンズアミド;
ii.4−(4−(6−アミノピリジン−3−イル)−6−モルホリノ−1,3,5−トリアジン−2−イルオキシ)−N,N−ジメチルベンズアミド;
iii.(S)−4−((4−(2−アミノチアゾール−5−イル)−6−(3−メチルモルホリノ)−1,3,5−トリアジン−2−イル)オキシ)−3−フルオロ−N,N−ジメチルベンズアミド;及び
iv.(S)−4−((4−(6−アミノピリジン−3−イル)−6−(3−メチルモルホリノ)−1,3,5−トリアジン−2−イル)オキシ)−3−フルオロ−N,N−ジメチルベンズアミド。 - PI3キナーゼ/mTORを有する抗癌化合物が、以下の化合物からなる群から選択される、請求項1及び5に記載の組合せ:
- 請求項1に記載の組合せと薬学的許容される賦形剤を含む医薬組成物。
- 癌を治療するための、請求項9に記載の医薬組成物。
- 抗癌組合せに対する患者の耐性の発症リスクを減少させるための、請求項9に記載の医薬組成物。
- 肥満に関連する効果を減少させるための、請求項9に記載の医薬組成物。
- 癌細胞に対する免疫応答を誘導するための、請求項9に記載の医薬組成物。
- ワールブルク効果を減少させるための、請求項9に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201611037375 | 2016-11-01 | ||
IN201611037375 | 2016-11-01 | ||
PCT/IN2017/050506 WO2018083713A1 (en) | 2016-11-01 | 2017-11-01 | Composition comprising combination of epicatechin and anti-cancer compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019536767A JP2019536767A (ja) | 2019-12-19 |
JP2019536767A5 true JP2019536767A5 (ja) | 2020-12-03 |
Family
ID=62076542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019523821A Pending JP2019536767A (ja) | 2016-11-01 | 2017-11-01 | エピカテキン及び抗癌化合物の組合せを含む組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190262347A1 (ja) |
EP (1) | EP3535252A4 (ja) |
JP (1) | JP2019536767A (ja) |
CN (1) | CN110312709A (ja) |
WO (1) | WO2018083713A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012170430A1 (en) | 2011-06-06 | 2012-12-13 | Cardero Therapeutics, Inc. | Methods and compositions for treatment of mitochondrial toxicity |
US20180193306A1 (en) | 2012-03-23 | 2018-07-12 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders and bone disorders |
JP6781148B2 (ja) | 2014-07-23 | 2020-11-04 | スファエラ ファーマ プライベート リミテッド | ヒドロキシステロイド化合物、それらの中間体、それらの調製方法、組成物および使用 |
US10898465B2 (en) | 2016-06-21 | 2021-01-26 | Epirium Bio Inc. | Utility of (+) epicatechin and their analogs |
CN113227067A (zh) | 2018-10-24 | 2021-08-06 | 埃皮里姆生物股份有限公司 | 包含表儿茶素和羧基-n-杂环共晶体形成剂的共晶体 |
JP6746022B1 (ja) * | 2020-02-13 | 2020-08-26 | シーシーアイホールディングス株式会社 | 腫瘍細胞におけるアスパラギン酸合成の阻害剤、腫瘍細胞のスフェロイド形成阻害剤、腫瘍細胞の転移抑制剤、解糖系阻害剤の作用増強剤、並びに腫瘍の転移の抑制および/または予防用医薬組成物 |
CN115025236B (zh) * | 2022-05-09 | 2024-03-08 | 聊城大学 | 一种加载化疗药物-茶多酚联合药物的pH响应型靶向DNA纳米载药体系 |
WO2024036223A1 (en) | 2022-08-10 | 2024-02-15 | Epirium Bio Inc. | Epicatechin inhibiting atp hydrolysis |
WO2024036225A1 (en) | 2022-08-10 | 2024-02-15 | Epirium Bio Inc. | Epicatechin for inhibiting glutamate toxicity |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011105763A (ja) * | 2000-06-21 | 2011-06-02 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
US7192612B2 (en) * | 2001-02-22 | 2007-03-20 | Purdue Research Foundation | Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer |
US20070054868A1 (en) * | 2005-06-20 | 2007-03-08 | The Trustees Of Columbia University In The City Of New York | Synergistic polyphenol compounds, compositions thereof, and uses thereof |
US9630958B2 (en) * | 2012-07-23 | 2017-04-25 | Sphaera Pharma Pte. Ltd. | Triazine compounds |
-
2017
- 2017-11-01 US US16/345,790 patent/US20190262347A1/en not_active Abandoned
- 2017-11-01 JP JP2019523821A patent/JP2019536767A/ja active Pending
- 2017-11-01 EP EP17867283.8A patent/EP3535252A4/en not_active Withdrawn
- 2017-11-01 WO PCT/IN2017/050506 patent/WO2018083713A1/en unknown
- 2017-11-01 CN CN201780081834.1A patent/CN110312709A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019536767A5 (ja) | ||
JP2020504742A5 (ja) | ||
ES2576289T3 (es) | Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer | |
Rodriguez et al. | Small cell lung cancer: past, present, and future | |
Monneret | Platinum anticancer drugs. From serendipity to rational design | |
DK2799070T3 (en) | EFFECTIVE AMPLIFIER FOR ANTITUMUM AGENTS | |
JP2018505169A5 (ja) | ||
TWI798199B (zh) | 癌症治療 | |
Bayati et al. | Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells | |
JP2013527232A5 (ja) | ||
RU2007145932A (ru) | Способ лечения устойчивого к лекарственным средствам рака | |
JP2019536767A (ja) | エピカテキン及び抗癌化合物の組合せを含む組成物 | |
TW200803842A (en) | Antineoplastic combinations of temsirolimus and sunitinib malate | |
JP2008528468A5 (ja) | ||
JP2019532051A5 (ja) | ||
Melisi et al. | Pancreatic cancer: systemic combination therapies for a heterogeneous disease | |
JP2012515184A (ja) | 大腸がんの治療方法 | |
JP2021510725A5 (ja) | ||
JP2007531728A5 (ja) | ||
JP2019509253A5 (ja) | ||
WO2017184086A1 (en) | Method of treating liver cancer | |
JP2023022190A (ja) | 癌治療 | |
JP2019513812A5 (ja) | ||
JP2017532308A5 (ja) | ||
JP6978251B2 (ja) | がん治療 |